secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000318154-22-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q2 2022: GAAP EPS $2.45, revenue $6.6B; guidance updated; non-GAAP policy change
--------------------------------------------------------------------------------

- Total revenues $6.6B (+1% YoY); product sales +3% driven by Repatha, Prolia, LUMAKRAS, EVENITY.
- GAAP EPS $2.45 vs $0.81 YoY; non-GAAP EPS $4.65 vs $1.77 YoY; free cash flow $1.7B flat.
- 2022 revenue guidance revised to $25.5-$26.4B; non-GAAP EPS reaffirmed $17-$18.
- Updated non-GAAP policy excludes upfront/milestone payments; prior 2021 non-GAAP EPS recast to $13.92 from $17.10.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815422000039/0000318154-22-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815422000039/amgn-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000318154-22-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer